EcoDrugPlus

Solute Carrier Family 5 Member 1

Ensembl ID : ENSMAMG00000009728
Gene Symbol: SLC5A1
3 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSMAMG00000012889
Gene Symbol: SLC5A2
3 Cross references
198 Possible Orthologues:

Solute Carrier Family 6 Member 1a

Ensembl ID : ENSMAMG00000024110
Gene Symbol: SLC6A1A
3 Cross references
205 Possible Orthologues:

Solute Carrier Family 6 Member 1b

Ensembl ID : ENSMAMG00000014523
Gene Symbol: SLC6A1B
3 Cross references
209 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSMAMG00000003500
Gene Symbol: SLC6A2
3 Cross references
203 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSMAMG00000024023
Gene Symbol: SLC6A3
3 Cross references
166 Possible Orthologues:

Solute Carrier Family 6 Member 4a

Ensembl ID : ENSMAMG00000002602
Gene Symbol: SLC6A4A
3 Cross references
201 Possible Orthologues:

Solute Carrier Family 6 Member 9

Ensembl ID : ENSMAMG00000015117
Gene Symbol: SLC6A9
3 Cross references
208 Possible Orthologues:

Solute Carrier Family 9 Member A3

Ensembl ID : ENSMAMG00000005643
Gene Symbol: SLC9A3
3 Cross references
234 Possible Orthologues:

Somatostatin Receptor 2a

Ensembl ID : ENSMAMG00000000597
Gene Symbol: SSTR2A
2 Cross references
192 Possible Orthologues:

Somatostatin Receptor 3

Ensembl ID : ENSMAMG00000020212
Gene Symbol: SSTR3
2 Cross references
188 Possible Orthologues:

Somatostatin Receptor Type 2-Like

Ensembl ID : ENSMAMG00000021582
Gene Symbol: LOC113141224
2 Cross references
192 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).